Therapeutically, RAAS blockade using angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) remains the cornerstone of treatment for hypertension-related kidney disease. This evidence concerns the gene ACE and kidney disorder.